Xenon (XP0) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

XP0 Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Xenon

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

XP0 Stock 12 Month Forecast

Average Price Target

€66.95

▲(22.85% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Xenon in the last 3 months. The average price target is €66.95 with a high forecast of €77.25 and a low forecast of €54.08. The average price target represents a 22.85% change from the last price of €54.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"€25","78":"€78","38.25":"€38.3","51.5":"€51.5","64.75":"€64.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":77.2524234,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€77.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.95210028,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€66.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.07669638,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€54.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,38.25,51.5,64.75,78],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.5,57.17326333846154,58.84652667692308,60.519790015384615,62.19305335384615,63.86631669230769,65.53958003076923,67.21284336923077,68.8861067076923,70.55937004615384,72.23263338461538,73.90589672307692,75.57916006153846,{"y":77.2524234,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.5,56.38093079076923,57.26186158153846,58.14279237230769,59.02372316307692,59.90465395384615,60.785584744615385,61.66651553538461,62.547446326153846,63.42837711692307,64.3093079076923,65.19023869846154,66.07116948923077,{"y":66.95210028,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.5,55.39051510615385,55.28103021230769,55.17154531846154,55.06206042461538,54.95257553076923,54.84309063692308,54.73360574307692,54.62412084923077,54.51463595538462,54.40515106153846,54.29566616769231,54.18618127384615,{"y":54.07669638,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€77.25

Average Price Target€66.95

Lowest Price Target€54.08

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Paul Matteis

Stifel Nicolaus

€73.82

Buy

35.45%

Upside

Reiterated

08/13/26

Xenon (XENE) Gets a Buy from Stifel Nicolaus

Tessa Romero

J.P. Morgan

€70.39

Buy

29.15%

Upside

Reiterated

08/11/26

J.P. Morgan Remains a Buy on Xenon (XENE)

Douglas Tsao

H.C. Wainwright

€63.52

Buy

16.55%

Upside

Reiterated

08/10/26

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)

Jason Gerberry

Bank of America Securities

€66.09

Buy

21.27%

Upside

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Relay Therapeutics (NASDAQ: RLAY) and Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)

Cory Kasimov

Evercore ISI

€68.67

Buy

26.00%

Upside

Reiterated

08/07/26

Evercore ISI Reaffirms Their Buy Rating on Xenon (XENE)

Serge Belanger

Needham

€66.95

Buy

22.85%

Upside

Reiterated

08/07/26

Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78

Myles Minter

William Blair

―

Buy

―

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE) and Solid Biosciences (NASDAQ: SLDB)

Yatin Suneja

Guggenheim

€77.25

Buy

41.75%

Upside

Reiterated

08/06/26

Xenon (XENE) Receives a Buy from Guggenheim

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Alector (NASDAQ: ALEC), Genmab (NASDAQ: GMAB) and Xenon (NASDAQ: XENE)

Brian Abrahams

RBC Capital

€70.39→€69.53

Buy

27.57%

Upside

Reiterated

08/06/26

Xenon (XENE) Receives a Buy from RBC Capital

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

€42.92→€54.08

Buy

-0.78%

Downside

Reiterated

06/22/26

Leerink Partners Sticks to Its Buy Rating for Xenon (XENE)

Benjamin Burnett

Wells Fargo

€59.23

Buy

8.67%

Upside

Reiterated

06/01/26

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Mirum Pharmaceuticals (NASDAQ: MIRM) and Corbus Pharmaceuticals (NASDAQ: CRBP)

Laura Chico

Wedbush

€54.08

Buy

-0.78%

Downside

Reiterated

05/08/26

Wedbush Reaffirms Their Buy Rating on Xenon (XENE)

David Hoang

Deutsche Bank

€48.07→€77.25

Buy

41.75%

Upside

Reiterated

03/10/26

Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche BankXenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank

Paul Choi

Goldman Sachs

€44.63→€64.38

Buy

18.12%

Upside

Reiterated

03/10/26

Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman SachsXenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Paul Matteis

Stifel Nicolaus

€73.82

Buy

35.45%

Upside

Reiterated

08/13/26

Xenon (XENE) Gets a Buy from Stifel Nicolaus

Tessa Romero

J.P. Morgan

€70.39

Buy

29.15%

Upside

Reiterated

08/11/26

J.P. Morgan Remains a Buy on Xenon (XENE)

Douglas Tsao

H.C. Wainwright

€63.52

Buy

16.55%

Upside

Reiterated

08/10/26

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)

Jason Gerberry

Bank of America Securities

€66.09

Buy

21.27%

Upside

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Relay Therapeutics (NASDAQ: RLAY) and Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)

Cory Kasimov

Evercore ISI

€68.67

Buy

26.00%

Upside

Reiterated

08/07/26

Evercore ISI Reaffirms Their Buy Rating on Xenon (XENE)

Serge Belanger

Needham

€66.95

Buy

22.85%

Upside

Reiterated

08/07/26

Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78

Myles Minter

William Blair

―

Buy

―

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE) and Solid Biosciences (NASDAQ: SLDB)

Yatin Suneja

Guggenheim

€77.25

Buy

41.75%

Upside

Reiterated

08/06/26

Xenon (XENE) Receives a Buy from Guggenheim

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Alector (NASDAQ: ALEC), Genmab (NASDAQ: GMAB) and Xenon (NASDAQ: XENE)

Brian Abrahams

RBC Capital

€70.39→€69.53

Buy

27.57%

Upside

Reiterated

08/06/26

Xenon (XENE) Receives a Buy from RBC Capital

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

€42.92→€54.08

Buy

-0.78%

Downside

Reiterated

06/22/26

Leerink Partners Sticks to Its Buy Rating for Xenon (XENE)

Benjamin Burnett

Wells Fargo

€59.23

Buy

8.67%

Upside

Reiterated

06/01/26

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Mirum Pharmaceuticals (NASDAQ: MIRM) and Corbus Pharmaceuticals (NASDAQ: CRBP)

Laura Chico

Wedbush

€54.08

Buy

-0.78%

Downside

Reiterated

05/08/26

Wedbush Reaffirms Their Buy Rating on Xenon (XENE)

David Hoang

Deutsche Bank

€48.07→€77.25

Buy

41.75%

Upside

Reiterated

03/10/26

Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche BankXenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank

Paul Choi

Goldman Sachs

€44.63→€64.38

Buy

18.12%

Upside

Reiterated

03/10/26

Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman SachsXenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xenon

3 Months

Serge BelangerNeedham

Success Rate

15/23 ratings generated profit

Average Return

+10.42%

Copying Serge Belanger's trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +10.42% per trade.

1 Year

Andrew TsaiJefferies

Success Rate

15/18 ratings generated profit

Average Return

+39.41%

Copying Andrew Tsai's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +39.41% per trade.

2 Years

Tessa RomeroJ.P. Morgan

Success Rate

12/14 ratings generated profit

Average Return

+30.91%

Copying Tessa Romero's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +30.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XP0 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, XP0 has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. XP0 average Analyst price target in the past 3 months is 66.95.

Each month's total comprises the sum of three months' worth of ratings.

XP0 Financial Forecast

XP0 Earnings Forecast

Next quarter’s earnings estimate for XP0 is -€0.97 with a range of -€1.11 to -€0.81. The previous quarter’s EPS was -€0.95. XP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XP0 has Performed in-line its overall industry.

XP0 Sales Forecast

Next quarter’s sales forecast for XP0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. XP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XP0 has Performed in-line its overall industry.

XP0 Stock Forecast FAQ

What is DE:XP0’s average 12-month price target, according to analysts?

Based on analyst ratings, Xenon’s 12-month average price target is 66.95.

What is DE:XP0’s upside potential, based on the analysts’ average price target?

Xenon has 22.85% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Xenon a Buy, Sell or Hold?

Xenon has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Xenon’s share price target?

The average share price target for Xenon is 66.95. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €77.25 ,and the lowest forecast is €54.08. The average share price target represents 22.85% Increase from the current price of €54.5.

What do analysts say about Xenon?

Xenon’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Xenon?

To buy shares of DE:XP0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Xenon (XP0) Stock Forecast & Price Target

XP0 Analyst Ratings

XP0 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Xenon

XP0 Analyst Recommendation Trends

XP0 Financial Forecast

XP0 Earnings Forecast

XP0 Sales Forecast

XP0 Stock Forecast FAQ

Detailed List of Analyst Forecasts